Literature DB >> 2073123

In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to seven fluoroquinolones.

J E Hoppe1, C G Simon.   

Abstract

The in vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to seven fluoroquinolones were assessed by the agar dilution method. Ciprofloxacin and temafloxacin were the most active compounds (MIC for 90% of isolates tested [MIC90], 0.06 microgram/ml), while enoxacin and pefloxacin were the least active (MIC90, 0.5 microgram/ml). Fleroxacin, lomefloxacin, and ofloxacin showed intermediate activities (MIC90s, 0.125 to 0.25 microgram/ml). These results suggest a possible role for the fluoroquinolones in the treatment of pertussis, at least in adult patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2073123      PMCID: PMC172042          DOI: 10.1128/AAC.34.11.2287

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Activity of new macrolides against Bordetella pertussis and Bordetella parapertussis.

Authors:  J E Hoppe; A Eichhorn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

Review 2.  Tissue penetration of the new quinolones in humans.

Authors:  D N Gerding; J A Hitt
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

3.  Antimicrobial susceptibilities of Bordetella species isolated in a Multicenter Pertussis Surveillance Project.

Authors:  T A Kurzynski; D M Boehm; J A Rott-Petri; R F Schell; P E Allison
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

4.  Susceptibility of Bordetella pertussis to five quinolone antimicrobic drugs.

Authors:  M E Appleman; T L Hadfield; J K Gaines; R E Winn
Journal:  Diagn Microbiol Infect Dis       Date:  1987-10       Impact factor: 2.803

5.  In vitro and in vivo activities of QA-241, a new tricyclic quinolone derivative.

Authors:  M Asahara; A Tsuji; S Goto; K Masuda; A Kiuchi
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

Review 6.  Use of quinolones in pediatric patients.

Authors:  D Adam
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

7.  In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to six new oral cephalosporins.

Authors:  J E Hoppe; J Müller
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

Review 8.  Potential role of fluoroquinolones in pediatric infections.

Authors:  S M Douidar; W R Snodgrass
Journal:  Rev Infect Dis       Date:  1989 Nov-Dec

9.  Fleroxacin: in-vitro activity worldwide against 20,807 clinical isolates and comparison to ciprofloxacin and norfloxacin.

Authors:  R Paganoni; C Herzog; A Braunsteiner; P Hohl
Journal:  J Antimicrob Chemother       Date:  1988-10       Impact factor: 5.790

10.  Comparative in vitro activity of lomefloxacin, a difluoro-quinolone.

Authors:  M J Robbins; A J Baskerville; M Sanghrajka; G Mumtaz; D Felmingham; G L Ridgway; R N Grüneberg
Journal:  Diagn Microbiol Infect Dis       Date:  1989 May-Jun       Impact factor: 2.803

  10 in total
  7 in total

Review 1.  State of art in antibacterial susceptibility of Bordetella pertussis and antibiotic treatment of pertussis.

Authors:  J E Hoppe
Journal:  Infection       Date:  1998 Jul-Aug       Impact factor: 3.553

2.  In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to BAY 12-8039, trovafloxacin, and ciprofloxacin.

Authors:  J E Hoppe; A Dalhoff; D Pfründer
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

Review 3.  Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A N Wadworth; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

4.  Update of epidemiology, diagnosis, and treatment of pertussis.

Authors:  J E Hoppe
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-03       Impact factor: 3.267

5.  Comparison of media for agar dilution susceptibility testing of Bordetella pertussis and Bordetella parapertussis.

Authors:  J E Hoppe; T Tschirner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-09       Impact factor: 3.267

6.  In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to four fluoroquinolones (levofloxacin, d-ofloxacin, ofloxacin, and ciprofloxacin), cefpirome, and meropenem.

Authors:  J E Hoppe; E Rahimi-Galougahi; G Seibert
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 7.  Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.

Authors:  J A Balfour; P A Todd; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.